Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 8.91 Billion | USD 14.74 Billion | 6.51% | 2022 |
FrequentlyAsked Questions
Methenamine hippurate tablets are medicines that are used for the treatment or prevention of urinary tract infections (UTIs) caused by bacteria.
The global methenamine hippurate tablets market is projected to grow owing to the increasing prevalence of UTIs across the globe.
According to study, the global methenamine hippurate tablets market size was worth around USD 8.91 billion in 2022 and is predicted to grow to around USD 14.74 billion by 2030.
The CAGR value of methenamine hippurate tablets market is expected to be around 6.51% during 2023-2030.
The global methenamine hippurate tablets market is expected to register the highest growth in North America owing to the growing prevalence of urinary tract infections.
The global methenamine hippurate tablets market is home to players like Almirall, S.A., Mylan N.V., Merck & Co., Inc., Cadila Healthcare Ltd., Pfizer Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., West-Ward Pharmaceuticals Corp., Abbott Laboratories, Glenmark Pharmaceuticals Ltd., Bausch Health Companies Inc., Procter & Gamble Co., Jubilant Life Sciences Ltd., Lupin Pharmaceuticals, Inc., Cipla Ltd., Amneal Pharmaceuticals LLC., Allergan plc., Novartis AG., and Sanofi S.A.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed